| Identification | Back Directory | [Name]
25-hydroxycholesterol-3-sulfate | [CAS]
884905-07-1 | [Synonyms]
Larsucosterol
25-hydroxycholesterol-3-sulfate
Cholest-5-ene-3,25-diol, 3-(hydrogen sulfate), (3β)- | [Molecular Formula]
C27H46O5S | [MOL File]
884905-07-1.mol | [Molecular Weight]
482.72 |
| Chemical Properties | Back Directory | [density ]
1.16±0.1 g/cm3(Predicted) | [storage temp. ]
-20°C | [form ]
powder | [pka]
-3.51±0.18(Predicted) | [InChIKey]
OEGAOHNRCSZIRO-KSGNISEOSA-M | [SMILES]
[H][C@@]12[C@]([C@](CC[C@H](OS(=O)([O-])=O)C3)(C)C3=CC2)([H])CC[C@@]4(C)[C@@]1([H])CC[C@]4([H])[C@]([H])(C)CCCC(C)(O)C.[Na+] |
| Hazard Information | Back Directory | [Uses]
25-hydroxycholesterol-3-sulfate has been used to induce anti-inflammatory responses and understand its effect on lymphocyte migration. It has also been used as an oxysterol sulfate standard in mass spectroscopy and liquid chromatography methods. | [Biological Activity]
25-hydroxycholesterol-3-sulfate (25OHC3S) is involved in lipid homeostasis in liver and is a lipid metabolism regulator. 25OHC3S acts on liver X receptor (LXR) and sterol regulatory element-binding protein (SREBP) and inhibits cholesterol synthesis by downregulating enzymes of the biosynthesis pathway in hepatocytes and macrophages. It also acts an agonist for peroxisome proliferator-activated receptor γ (PPAR-γ) and modulates the nuclear factor K-light-chain-enhancer (NF-KB) based inflammatory response. 25OHC3S modulates tumor necrosis factor α (TNFα)-induced inflammatory response in hepatocytes. | [in vivo]
Larsucosterol (DUR-928; 25 mg/kg; i.p.; twice in 14 hours; C57BL/6J mice with nonalcoholic fatty liver diseases (NAFLD) model) reduces serum lipid levels in mice fed a high-fat diet[3].
Larsucosterol (25 mg/kg; i.p.; twice in 14 hours; C57BL/6J mice with nonalcoholic fatty liver diseases (NAFLD) model) suppressed the expression of the genes and inhibits ABCA1 expressionde. Larsucosterolcreases nuclear SREBP-1 Protein levels and cytoplasmic FAS and ACC1 protein levels in liver tissue[3].
Larsucosterol (25 mg/kg; i.p.; once every 3 days for 6 weeks; C57BL/6J mice with nonalcoholic fatty liver diseases (NAFLD) model) protects the liver from injury by suppressing hepatic inflammation[3].
| Animal Model: | Female C57BL/6J mice with nonalcoholic fatty liver diseases (NAFLD) model[3] | | Dosage: | 25 mg/kg | | Administration: | Intraperitoneal injection; once every 3 days for 6 weeks | | Result: | Decreased plasma cholesterol levels.
Reduced serum alkaline phosphatase, ALT, and AST levels.
|
| Animal Model: | Female C57BL/6J mice with nonalcoholic fatty liver diseases (NAFLD) model[3] | | Dosage: | 25 mg/kg | | Administration: | Intraperitoneal injection; twice in 14 hours | | Result: | Decreased plasma TG, CHOL, and HDL-C by 40, 15, and 20%, respectively.
Reduced the mRNA levels of SREBP-1c, ACC1, and FAS by 46, 57, and 49%, respectively.
Suppressed ABCA1 expression.
Suppressed nuclear SREBP-1, cytoplasmic ACC1, and FAS protein levels by 74, 58, and 47%, respectively.
|
|
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
| Company Name: |
Creative Enzymes
|
| Tel: |
1-516-855-7709 |
| Website: |
www.creative-enzymes.com |
|